PARP INHIBITOR BIOMARKERS MARKET ANALYSIS

PARP Inhibitor Biomarkers Market, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others)), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI3762
Pages :176
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market Challenges And Opportunities

Challenges And Opportunities

Restratnts:

High cost of PARP inhibitor biomarker test kits and assays

High cost of PARP inhibitor biomarker test kits and assays is expected to hamper the growth of the global PARP inhibitor biomarkers market. For instance, in May 2020, Myriad Genetics, Inc.'s myChoice CDx became commercially available with a list price of US$ 4,590. myChoice CDx is the FDA has approved myChoice CDx for use as a companion diagnostic to identify patients with advanced ovarian cancer with positive homologous recombination deficiency (HRD) status by detecting BRCA1 and BRCA2.